Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Idexx Laboratories (IDXX)

IDEXX names Michael Erickson CEO, succeeding Jay Mazelsky effective May 12, 2026

Neutral Impact 4 of 5 leadership Written later

IDEXX Laboratories said Michael (Mike) Erickson, PhD, will become President and Chief Executive Officer on May 12, 2026, replacing Jonathan (Jay) Mazelsky, who will become Executive Chair of the Board. Mazelsky plans to retire from the company and the Board immediately after the annual shareholder meeting in May 2027, and Erickson will join the Board as a Class II Director.

Key points

  • Erickson, 52, has worked at IDEXX since 2011 and currently serves as Executive Vice President and General Manager of Global Point of Care Diagnostics and Telemedicine.
  • Erickson's letter agreement sets an annualized base salary of $1,000,000 and a bonus target of 120% of base salary, with an expected 2026 long-term equity award of not less than $7.8 million.
  • Mazelsky's letter agreement sets a base salary of $1,150,000 as Executive Chair, with an expected 2026 time-vesting restricted stock unit grant of not less than $8.275 million.
  • Lawrence D. Kingsley, the current independent Non-Executive Chair, will serve as independent Lead Director from the transition date.

The filing

CompanyIdexx Laboratories (IDXX)
Form8-K, current report
Filed with the SECJan 13, 2026, 8:33 AM ET
Accession number0001104659-26-003103

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.